Day 1 | 11th Annual Clinical Cancer Genetics and Genomics Conference
The introduction of affordable next generation sequencing (NGS) applications, including multi-gene panels, tumor profiling for targeted therapeutics, and whole exome/genome analyses, is ushering in complex data on both rare and common genetic variants of intermediate penetrance into the arena of clinical medicine. These applications are rapidly changing the landscape of personalized cancer risk assessment, treatment and preventive care.
Identifying hereditary cancer predisposition through genomic cancer risk assessment (GCRA) allows for intensified measures to prevent cancers or detect them at an earlier, more treatable stage, and both germline and somatic/tumor testing may guide precision therapy. The rapid advances of next generation sequencing (NGS) technologies and market forces are driving a surge in demand for GCRA services across the nation, but few clinicians are adequately prepared with the knowledge and skills needed to address the complexities associated with multigene panel testing and approaches that combine tumor and germline genomic profiles. This two-and-a half day conference will bring a roster of nationally recognized speakers together with community-based clinicians from across the U.S. to explore the promise and challenge of incorporating NGS technologies into the landscape of personalized cancer risk assessment, treatment and preventive care.
This activity is designed for oncologists/physicians, physician assistants, nurse practitioners, genetic counselors and other health care professionals involved in clinical genetic cancer risk assessment and/or precision medicine services in their health care system.
- Explore innovative approaches to implementing broad genomic analyses for precision medicine in patient care.
- Discuss the clinical utility of emerging tools for cancer detection, including liquid biopsy and targeted imaging.
- Identify the benefits and limitations of evolving methods for genetic analysis, including tumor/germline, polygenic risk scores, and pharmacogenomics testing.
- Apply evidence-based cancer risk management, prevention, and targeted therapeutics recommendations for clinical cases.
- Explore challenges and solutions related to diversity, equity, and inclusion in high-risk patient care in the U.S. and globally.
- Recognize disease-specific advances in identifying and managing individuals with hereditary cancer syndromes including breast/ovarian, gastrointestinal, hematologic, and other cancer syndromes.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 20.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 20.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any ineligible company. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, that could create a conflict of interest, and an "ineligible company" as any entity producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Any potential conflicts relative to the previous disclosure have been resolved.
Written disclosure of all such relevant financial relationships will be provided in the activity handout and/or syllabus. Any potential conflicts relative to the previous disclosure have been resolved.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.